Lexicon Pharmaceuticals, Inc. LXRX
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a cardio-renal-metabolic drug developer. Its lead program, sotagliflozin for hypertrophic cardiomyopathy, is in Phase 3 for hypertrophic cardiomyopathy (HCM). Its next catalyst on record is Hercules term loan: Minimum cash covenant begins (June 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Hercules term loan — Minimum cash covenant begins (June 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INPEFA (sotagliflozin) | heart failure / type 2 diabetes with CKD | small molecule | Approved |
| sotagliflozin (SONATA-HCM) | hypertrophic cardiomyopathy | small molecule | Phase 3 |
| ZYNQUISTA (sotagliflozin) | type 1 diabetes | small molecule | Phase 3 |
| pilavapadin | diabetic peripheral neuropathic pain (DPNP) | small molecule | Phase 2 |
| LX9851 | obesity and associated cardiometabolic disorders | small molecule | Phase 1 |
Recent results and decisions
- Nov 5, 2026completed enrollment SONATA-HCM Phase 3 study in symptomatic obstructive and non-obstructive HCM completed enrollment with 542 patients, substantially exceeding planned enrollment.
Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study in patients with symptomatic obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy. The trial enrolled a total of 542 patients across both nHCM and oHCM, substantially exceeding its planned en
Filing - Nov 5, 2026positive STENO1 investigator-initiated study achieved patient exposure and safety requirements for ZYNQUISTA NDA resubmission, with positive safety data showing low rates of DKA comparable to standard of care.
STENO1, a third-party funded, investigator-initiated study of sotagliflozin being conducted by the STENO Diabetes Center (Denmark) has achieved the patient exposure and safety data requirements agreed upon with the U.S. Food and Drug Administration (FDA) to support resubmission of the Company's New
Filing - Aug 6, 2026completed enrollment Enrollment completed in Phase 3 SONATA-HCM, substantially exceeding the 500-patient target, with a majority of non-obstructive HCM patients; topline expected Q1 2027.
Enrollment has been completed in SONATA-HCM, a pivotal Phase 3 placebo-controlled study, substantially exceeding its enrollment target of 500 patients across both non-obstructive (nHCM) or obstructive HCM (oHCM).
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.